India's Glenmark Pharmaceuticals has launched the first and only generic version of Zetia -- Merck's cholesterol drug -- in the U.S. market.
Glenmark and licensing partner Endo International will be entitled to 180 days of generic drug exclusivity for ezetimibe in the U.S. market. According to IMS Health data for the 12-month period ending October 2016, annual U.S. sales of Zetia 10 mg were approximately $2.3 billion.
Glenmark, headquartered in Mumbai, has a current portfolio consisting of 111 products authorized for distribution in the U.S.
Read the ET article